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T cell–mediated immune responses require the 
active migration of T cells in tissues and the es-
tablishment of specifi  c cell–cell contacts with 
other cell types. T cell migration was analyzed 
intravitally in the last few years using noninva-
sive two-photon microscopy (1–3). In lymph 
nodes, T lymphocytes move using an “ameboid”-
like migration mode and display extremely high 
instantaneous velocities (up to 25 μm/min) 
(4, 5) compared with DCs or tumor cells (6, 7). 
The resulting high mean velocities allow naive 
T cells to “scan” high numbers of DCs seeking 
for their MHC-peptide ligands (8, 9). Once a 
specifi  c ligand was encountered, T cells stop 
their migration and establish antigen-specifi  c 
contacts with DCs. The duration of these con-
tacts is determined by the maturation state of 
the interacting DCs and the eventual presence 
of regulatory T cells. In most experimental sys-
tems, long lasting (hours) contacts occurred 
during the induction of eff  ective priming (4, 5, 9), 
whereas short interactions (minutes) were ob-
served in tolerogenic conditions (10, 11) or 
in the presence of regulatory T cells (12, 13). 
Shakar et al. (14), however, only found modest 
diff  erences in the mobility of CD4+ T cells 
during the induction of priming and tolerance.
During antiviral, antitumor, or autoimmune 
responses, for example, diff  erentiated  eff  ector 
T cells migrate in nonlymphoid tissues to inter-
act with target cells. Similar to lymph nodes, 
eff  ector T cell migration in rat spinal cord 
sections during experimental autoimmune en-
cephalomyelitis displays “ameboid” charac-
teristics and high mean velocities, showing 
  antigen-specifi  c arrests upon autoantigen rec-
ognition within the spinal cord (15). Few stud-
ies also analyzed the eff  ector phases of immune 
responses by NK T cells or NK cells (16, 17). 
The killing of target cells by cytotoxic T lym-
phocytes was recently imaged in lymph nodes. 
Regulatory T cells were thus shown to reduce 
the killing effi     ciency of CTLs by interfering 
with the polarized secretion of cytotoxic gran-
ules (18). The traffi   cking of CD8+ cytotoxic T 
cells in tumor- bearing mice was analyzed recently 
using magnetic resonance or positron-emission 
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tomography imaging (19–21), but the actual resolution of 
these methods is too low for single cell imaging. CTL-
  mediated cytotoxicity in solid tumors, in contrast, has not 
been imaged thus far.
Although adoptive transfer of T cells induces the rejec-
tion of established solid tumors, both in murine models and 
in cancer patients (22–25), very little is known about the ac-
tual mechanisms of tumor invasion by CTLs and rejection. 
For example, the relative contribution of direct tumor cell 
killing by cytotoxic T cells compared with killing by other ef-
fectors of innate immunity is still uncertain (26, 27). Various 
hematopoietic cells, including macrophages, natural killers, 
and neutrophiles, were shown to infi  ltrate the tumors after 
CTL responses (28, 29).
To analyze the infi  ltration and tumor cell killing in solid 
tumors, we used a combination of tumor cells and CTLs 
  expressing recombinant fl  uorescent proteins. Both conven-
tional and intravital, one- and two-photon microscopy al-
lowed us to image the dynamics of CTL motility and tumor 
infi  ltration by CTLs. We thus describe a complex, antigen-
dependent   topography of invasion and motility of CTLs in 
solid tumors.
RESULTS
OT1-GFP cells infi  ltrate and reject OVA-expressing tumors
To analyze the role of antigen recognition in tumor infi  ltra-
tion and in CTL motility within tumors, we inoculated indi-
vidual C57BL/6 mice s.c. with two tumors: the EL4 thymoma 
in one fl  ank and the EG7 (OVA-expressing EL4 cells) in the 
other fl   ank. Naive GFP-expressing, OVA-specifi  c,  TCR-
transgenic OT1 cells (OT1-GFP) were adoptively transferred 
to the mice when the EL4 and EG7 tumors were 500–1,000 
mm3 (around day 10). OT1-GFP cells induced the complete 
rejection of EG7, but not of EL4 tumors, within 6–8 d (Fig. 
1 A). After the adoptive transfer of OT1-GFP cells, the tu-
mors continued to grow for 3 d. After 3–4 d, the tumor stops 
growing before the size actually starts decreasing at days 5–6. 
At days 7–8, the tumors continued to shrink and disappeared 
completely. We defi  ned two periods for the analysis of the 
active rejection process: the “early” rejection phase corre-
sponds to days 3–4 after adoptive transfer when the tumor 
stops growing; the “late” rejection phase corresponds to days 
5–6 when the size of the tumors starts to decrease, but before 
complete rejection (which occurs at days 7–8).
We fi  rst sought to analyze the activation of the transferred 
OT1 cells in the draining lymph node or nondraining lymph 
node EG7 tumors. As shown in Fig. S1 (available at http://
www.jem.org/cgi/content/full/jem.20061890/DC1), OT1-
GFP cells are primed in EG7 draining lymph nodes but 
not in the nondraining ones. The transferred cells transiently 
up-regulate CD69, maintain high levels of CD44, and dis-
play decreased CD62L expression (Fig. S1, A and B and ref-
erence 30). OT1 activation resulted in the expansion of the 
OT1-GFP cells up to fi  vefold at day 3 (0.37% ± 0.02 versus 
1.8% ± 0.3 of total cells; P = 0.005) (Fig. S2, available at 
http://www.jem.org/cgi/content/full/jem.20061890/DC1). 
Figure 1.  Activation of specifi  c T cells in antigen-expressing 
  tumors. C57Bl6 mice were injected s.c. with fi  ve 105 EG7 and EL4 tumor 
cells in either fl  ank. 8–10 d later, the mice were adoptively transferred with 
107 purifi  ed naive CD8+ cells from OT1-GFP mice. (A) Evolution of EG7 (■) 
and EL4 (□) tumor size after adoptive transfer. (mean ± SD, n = 5 indepen-
dent experiments). Early phase (day 3–4) and late phase (day 5–6) were 
defi  ned in Material and methods. (B) Density of OT1-GFP cells within EG7 
and EL4 at early (day 3) and late (day 6) phase of tumor rejection were 
calculated from tumor section by counting the number of OT1-GFP cells 
per mm2. (C) Expression of CD69 (hatch marked) and CD62L (gray) activa-
tion markers in GFP+ cells as analyzed by fl  ow cytometry (dLN, draining 
LN) (mean ± SD, n = 3–6). (D) IFN-γ production of GFP+ cells in EG7 
and EL4 tumors after 3 h of treatment with Brefeldin A without antigen 
restimulation (mean ± SD, n = 5). *, P < 0.05; **, P < 0.01; ***, P < 0.001.JEM VOL. 204, February 19, 2007  347
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The slight increase of OT1-GFP cell numbers in the spleen 
(0.20% ± 0.11 to 0.55% ± 0.1; P = 0.006) is probably caused 
by the recirculation of activated cells rather than a local 
  antigen-  induced expansion (30). Therefore, transferred OT1 
cells are selectively activated in the antigen-expressing tumor 
draining lymph nodes.
The infi  ltration of the tumors by the OT1 cells was ana-
lyzed next by measuring the density of OT1-GFP cells in 
frozen sections of either tumor at days 3–4 after adoptive 
transfer. Both EG7 and EL4 tumors were infi  ltrated with 
OT1-GFP cells (Fig. 1 B), consistent with the observation 
that activated primary CD8+ T cells migrate to nonlymphoid 
tissue regardless of their site of activation (31). The number 
of OT1-GFP cells infi  ltrating EG7 was, as expected, higher 
than the number infi  ltrating EL4, especially at day 6 after 
adoptive transfer (327 ± 50 cells/mm2 versus 27 ± 2 cells/
mm2) (Fig. 1 B). The OT1-GFP cells infi  ltrating both EL4 
and EG7 tumors expressed low levels of CD62L, attesting 
that both cell populations had been previously activated (Fig. 
1 C). In contrast, only the OT1-GFP cells infi  ltrating OVA-
expressing EG7 tumors, but not those infi  ltrating the EL4 tu-
mors, reexpressed high levels of the early activation marker 
CD69 (Fig. 1 C) and produced IFN-γ (Fig. 1 D). The EG7-
infi  ltrating OT1-GFP cells, but not OT1-GFP cells infi  ltrat-
ing EL4, also down modulated their TCR, as attested by 
the decreased expression of Vβ5 (Fig. S3, available at http://
www.jem.org/cgi/content/full/jem.20061890/DC1). We 
conclude that the parallel inoculation of antigen-expressing 
and antigen-nonexpressing tumors to the same mouse in-
duced the infi  ltration of both tumors, although the T cells 
accumulated preferentially in the antigen-expressing tumors. 
T cell activation and eff  ector function (CD69 expression, 
IFN-γ production, and killing), however, were only detect-
able in CTLs infi  ltrating the antigen-bearing tumors.
Antigen expression determines the motility 
of CTLs in tumors
To investigate the role of antigen recognition in the motility 
of antigen-specifi  c CTLs within tumors, we next performed 
intravital time-lapse two-photon imaging. 8–10 d after s.c. 
injection of the tumors, OT1-GFP cells were adoptively 
transferred into tumor-bearing mice. At days 3–4 (early phase 
of rejection) or 5–6 (late phase of rejection) after adoptive 
transfer of OT1-GFP cells, the mice were anesthetized and 
injected i.v. with fl  uorescent dextran to visualize blood 
  vessels. As shown in Videos S1 and S2 (available at http://
www.jem.org/cgi/content/full/jem.20061890/DC1), during 
the early phase of rejection OT1-GFP moved   actively in 
EL4 tumors but had reduced motility in EG7 tumors. During 
the late phase of rejection, OT1-GFP cells moved actively 
in both tumors (Videos S3 and S4, available at http://
www.jem.org/cgi/content/full/jem.20061890/DC1). Indi-
vidual cell trajectories were tracked (representative examples 
are shown in Fig. 2, A and B), and the mean velocity, arrest 
coeffi   cient (the proportion of time every individual remains 
arrested), and confi  nement ratio (the ratio of the distance 
  between the initial and the fi  nal positions of each cell to the 
total distance covered by that cell) were determined (Fig. 2 C).
During the early phase of rejection, OT1-GFP cells 
moved with a mean velocity of 4 ± 2 μm/min in the EG7 
tumors compared with 10 ± 4 μm/min in the EL4 tumors. 
The migration trajectories were more restrained in the EG7 
compared with the EL4 tumors (confi  nement ratios of 0.4 ± 
0.2 versus 0.6 ± 0.2). Consistently, the arrest coeffi   cient 
was higher in EG7 (33 ± 17%) than in EL4 (13 ± 17%) 
  tumors. During the late phase of rejection, the motility of 
OT1-GFP cells in EG7 increased to 8 ± 3 μm/min−1 to 
become similar to the mean velocity of OT1-GFP cells in 
EL4 tumors (10 ± 5 μm/min−1). The migration trajectories 
also became less confi  ned (0.6 ± 0.2) and identical to the 
ones observed in EL4 tumors. Finally, the arrest coeffi   cient 
in EG7 tumors dropped to 14 ± 16%, which is close to that 
of OT1-GFP cells in EL4 tumors (16 ± 21%). We conclude 
that CTLs transiently stop moving in antigen-expressing 
  tumors during the early phase and then resume their migra-
tion during the late phase when the size of the tumor starts 
to decrease.
OT1-GFP stop in contact with OVA-expressing 
tumor cells
To investigate if this transient arrest of migration in the 
  antigen-expressing tumors is related to the killing of tumor 
cells by the CTLs, EG7 and EL4 tumor cells were transfected 
with GFP-encoding plasmid. The GFP-expressing tumors 
behaved like their GFP-negative counterparts in terms of 
  tumor growth and rejection after transfer of OT1 cells. Tumor 
cell viability in vivo was determined at diff  erent time points 
by the level and the distribution of intracellular GFP using 
two-photon microscopy. During the early phase of tumor 
rejection, tumor cells formed a dense network of bright liv-
ing cells in both EL4-GFP and EG7-GFP tumors, similar to 
that observed in the absence of OT1 cells (Fig. 3 A). In the 
late phases of rejection, in contrast, EG7 tumors, but not EL4 
tumors, were mainly composed of residual dead tumor cells—
i.e., cells displaying lower GFP levels and a GFP-negative, 
compact nucleus. In EG7 tumors during the late phase, the 
enhanced second harmonic generation (SHG) signal refl  ected 
an increase in the density of collagen fi  bers (Fig. 3 A), sug-
gesting increased fi  brosis in this region of the tumor.
To determine if the cells expressing low levels of GFP 
observed in the late phase were dead tumor cells or macro-
phages having engulfed dead tumor cells, we injected the 
  tumor-bearing mice with propidium iodide (PI). As shown 
in Fig. 3 B, in EG7 tumors during the early phase, when most 
tumor cells are still alive, few cells are stained with PI. During 
the late phase, in contrast, all cells displaying low levels of 
GFP with dark GFP-negative nuclei are labeled by PI (Fig. 
3 B). We conclude that during tumor rejection, dead tumor 
cells accumulate in the periphery of the tumors, most likely 
before being cleared by macrophages.
The change in the dynamics of OT1 cell motility in the 
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correspond to the arrests of OT1 cells during tumor cell killing. 
To investigate this possibility, we analyzed the dynamics of 
OT1 cells expressing cyan fl  uorescent protein (OT1-CFP) 
in tumors expressing GFP during the early or late rejection 
phases (Videos S5 and S6, available at http://www.jem.org/
cgi/content/full/jem.20061890/DC1). As shown in Fig. 4 A 
and Video S5, during the early phase the majority of the ar-
rested OT1-CFP cells are in contact with living EG7-GFP 
tumor cells. During the late phase, OT1-CFP cells seem to 
resume motility in regions where the tumor cells are dead 
(Fig. 4 B and Video S6). We therefore compared the dynamic 
of the OT1 cells in regions where the tumor cells are alive or 
dead. As shown in Fig. 4 C, the OT1-CFP cells displayed 
lower mean velocity (1.1 ± 0.4 μm/min) and confi  nement 
ratios (0.15 ± 0.05) and higher arrest coeffi   cients (82 ± 11%) 
in regions where the tumor cells are alive during early phase 
than in regions where the tumor cells are dead during late 
phase (mean velocity, 6.4 ± 2.5 μm/min; confi  nement ratio, 
0.7 ± 0.2; and arrest coeffi   cient, 17 ± 18%). During the late 
phase, we eventually found regions of the tumors where at 
least parts of the EG7-GFP cells are still alive. OT1-CFP cells in 
these regions only partially resumed motility compared with 
regions where most of the tumor cells were dead (Fig. 4 C).
The interactions between OT1-CFP and tumor cells 
were analyzed in more details by defi  ning four types of 
  trajectories. Fig. 4 D shows representative examples of cell 
trajectories falling into each of these four categories. The fi  rst 
trajectory corresponds to cells arrested in close contact with 
GFP-positive tumor cells (Fig. 4 D, Stable). The second one 
corresponds to cells that are not completely arrested, but 
move around a GFP-positive tumor cell, or interact with 
several neighboring tumor cells (Fig. 4 D, Confi  ned). The 
third one includes OT1 cells that interact transiently with 
several distant tumor cells (Fig. 4 D, Serial), and the fourth 
one corresponds to OT1 cells that do not establish any mea-
surable interaction with a tumor cell (Fig. 4 D, Fleet). After 
sorting the cells into these four categories, we analyzed their 
mean velocity, confi  nement ratio, and arrest coeffi   cient (Fig. 
S4). As expected, the two former parameters increased from 
categories 1 to 4, whereas the arrest coeffi   cient decreased.
Figure 2.  CTLs motility during tumor infi  ltration and clearance. 
(A) TPLSM images (260 × 260 μm) of OT1-GFP cells (green) within 
tumors (EG7 and EL4) of anesthetized mice at early (day 3) and late (day 5) 
time points after adoptive transfer. Vascular vessels are labeled by 70 kD 
rhodamine-dextran (red); typical migratory path (white) examples are shown. 
Bar, 47 μm. (B) Overlay of 50 individual T cell tracks plotted after aligning 
their starting positions. (C) Scatter plots of T cell mean velocity, confi  nement 
ratio, and arrest coeffi  cients of all cells analyzed. Data from two to four 
independent experiments were pooled (day 3: EG7, n = 675; EL4, n = 275; 
day 5: EG7, n = 1249; EL4, n = 126). ns, not signifi  cant. ***, P < 0.001.JEM VOL. 204, February 19, 2007  349
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The relative proportions of each type of OT1 categories 
were quantifi  ed during the early phase (in regions of the tu-
mors where tumor cells are alive) and during the late phase 
(in regions where most tumor cells are dead). As shown in 
Fig. 4 E, the proportion of OT1 cells in the fi  rst two cate-
gories (Fig. 4 D, Stable and Confi  ned) represents 95% in re-
gions of the tumor where the tumor cells are alive. In contrast, 
in regions where most tumor cells are dead, categories 3 and 4 
(Fig. 4 D, Serial and Fleet) represent  90% of the OT1 cells. 
Importantly, during the late phase, in regions of the tumor 
where part of the tumor cells were alive, OT1-CFP cells 
adopted an intermediate behavior, indicating again that re-
sumed motility OT1-CFP cells was dictated by the viability 
of the tumor cells rather than the day after adoptive transfer.
We conclude that during the early phase of tumor rejec-
tion, OT1 cells are in contact with living tumor cells, either 
completely arrested or following very constrained trajec-
tories, suggesting that they interact with several neighboring 
tumor cells. During the late phase of tumor rejection, in the 
regions where most tumor cells are dead, OT1 cells either 
make very short arrests or migrate rapidly within the tumor 
with no apparent stops. Therefore, resumed T cell motility in 
antigen-expressing tumors occurs preferentially in regions 
where the tumor cells are dead.
Modes of CTL migration in tumors
We next sought to characterize this resumed CTL migration 
in more detail. Resumed CTL motility in regions of the tu-
mor where the tumor cells are dead followed an amoeboid 
pattern (Videos S6 and S7, available at http://www.jem.org/
cgi/content/full/jem.20061890/DC1). We observed impor-
tant changes in the cell shape, suggesting a strong adaptation 
of the CTLs to the extracellular matrix and their ability to 
squeeze through narrow spaces as observed in artifi  cial three-
dimensional collagen matrix (32) or around stromal and tu-
mor cells. CTLs occasionally followed collagen fi  bers, which 
were visualized by their SHG signals (Video S6). We also 
observed OT1 cells dividing inside the EG7 tumors (0.8% of 
the tracked OT1 cells, n = 1,249; Video S8). Because our 
videos last 30 min, the proportion of divisions over 24 h 
could be relatively high (up to 30–40% of the OT1 cells, as-
suming the rate of divisions remains the same over this period 
of time). Divisions might have gone unnoticed in the EL4 
tumors because of the near 10-fold lower T cell population. 
Accumulation of tumor cells around blood vessels was ob-
served occasionally (Video S9), suggesting either regions of 
preferential CTL extravasation or chemotactism of CTLs for 
the blood vasculature. Three-dimensional reconstitution 
shows that CTLs are in close contact to blood vessels (Video 
S10). Strikingly, CTLs moved frequently along blood vessels 
(Video S7), adopting a more elongated morphology and un-
dergoing less important changes in their shape.
To characterize and quantify the cells migrating along 
blood vessels in more detail, we took advantage of certain re-
gions of the tumor periphery that displayed a highly orga-
nized blood vessel pattern orientated along one major axis 
(Fig. 5 A). In these areas, numerous CTLs maintained close 
contact with vessels during migration (Video S11, available at 
http://www.jem.org/cgi/content/full/jem.20061890/DC1) 
for relatively long distances (114 ± 63 μm, n = 17). The 
CTLs adopted an anisotropic migration pattern along the 
axis of the blood vessels as indicated by a higher correlation 
coeffi   cient (no-contact, r = 0.31 and contact, r = 0.73; 
P < 0.001) (Fig. 5 A, bottom). The ability of several cells 
to migrate from a blood vessel to another confi  rmed that 
the CTLs are probably not in the lumen of the vessels, but 
either in the tissue or within the “sheath” around the vessels. 
Migration along blood vessels proceeds with a mean velocity 
similar to that of the CTLs migrating at distance of visible 
blood vessels (8.2 ± 2.4 μm/min and 8.6 ± 2.8 μm/min, 
respectively; Fig. 5 B).
The shape of CTLs during migration along blood ves-
sels seemed to diff  er from their morphology in other areas 
of the tumor (examples are shown in Fig. 5 C, top, and 
Video S12, available at http://www.jem.org/cgi/content/
full/jem.20061890/DC1). Fig. 5 D, top, shows the evolution 
of the elongation index (ratio between the length and the 
Figure 3.  Tumor cell clearance during early and late phase. 
(A) Representative TPLSM images (160 × 160 μm) of GFP-EG7 or GFP-
EL4 tumors during early (day 3) and late phase (day 6) of tumor rejection 
after adoptive transfer of 107 OT1 cells. Vessels (red) are imaged by intra-
venous injection of 70 kD rhodamine-dextran (2.5 μg/ml) and collagen 
fi  bers (blue) using SHG signals. Capture parameters were identical for 
all images. Bar, 44 μm. (B) TPLSM images (150 × 150 μm) of GFP-EG7 
(green) during early (day 4) and late (day 6) phase of rejection after intra-
tumoral injection of propidium iodide (blue). Bar, 41 μm.350  IN VIVO CYTOTOXIC T CELL IMAGING IN TUMORS | Boissonnas et al.
breadth of a cell) of two representative cells migrating either 
in contact or at distance from a blood vessel. Cells in contact 
with blood vessels were more elongated, displaying a higher 
elongation index (1.9 ± 0.2) than cells crawling at distance 
from visible blood vessels (1.6 ± 0.1) (Fig. 5 C, bottom). 
To investigate if the shape of individual cells changes when 
they migrate in contact or at distance of a blood vessel, we 
followed the elongation index of individual cells migrating 
in the same videos in contact or at distance of a vessel (Fig. 
5 D, bottom). As long as the cell is at distance from any vis-
ible vessel, its elongation index is <2 for most of the time, 
and occasionally rises over this value for short periods of time 
(<1 min). When the cell starts migrating in close vicinity to 
the blood vessel, its elongation index rises to values >2 for 
several min. The elongation index then falls to  2, whereas 
the cell is still migrating along the same blood vessel. For this 
particular cell, the diff  erence in the elongation index before 
and after the initiation of the contact with the blood vessel 
is statistically signifi  cant (P = 0.0015). A signifi  cant increase 
in the elongation index before and after the initiation of the 
contact with the blood vessel, however, was only observed in 
three out of fi  ve cells analyzed.
Figure 4.  Dynamics of CTL interactions with tumor cells. TPLSM 
images of OT1-CFP cells (A, blue; B, magenta) within EG7-GFP tumors 
(green) during early phase (day 4) and late phase (day 5) of tumor rejection. 
Collagen fi  bers (blue) are imaged by SHG. Examples of typical migratory 
paths (red) are shown. Bars: (A) 27 μm; (B) 39 μm. (C) Scatter plots of 
T cell mean velocity, confi  nement ratio, and arrest coeffi  cients of all cells 
analyzed. Data from three to four independent experiments were pooled. 
(Alive-Early, n = 20; Dead-Late, n = 121; Alive-Late, n = 77). ***, P < 0.001. 
(D) TPLSM images (90 × 90 μm) representing typical migratory paths 
(red) for each class of interaction as described in Material and methods 
(Stable, black; Confi  ned, dark gray; Serial, light gray; Fleet, white). Bar, 
28 μm. (E) Histograms representing the relative fraction of the different 
classes of interaction in areas displaying alive or dead tumor cells during 
the early (day 4) and the late phase (day 5) of tumor regression.JEM VOL. 204, February 19, 2007  351
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We conclude that single CTLs can migrate along blood 
vessels using high or low elongation indexes. Elongations 
indexes higher than 2 lasting for several min were only 
observed in cells migrating along blood vessels and not in 
cells migrating at distance of blood vessels. In the latter, 
the elongation index was very variable and eventually in-
creased over 2 for short periods of time, refl  ecting a higher 
deformability of the cells, most likely a result of constraints 
imposed by the extracellular matrix encountered during 
the crawling.
Deep infi  ltration in antigen-expressing tumors
Because two-photon imaging is technically restricted to peri-
pheral area of the tumors, we next sought to analyze the topo-
graphy of CTL infi  ltration deeper into the tumor and to 
analyze the role of antigen recognition in this process. To 
do so, we had to quantify infi  ltration by CTLs in regions of 
the tumor beyond the penetration limit of the two-photon 
microscope. We therefore made ordered sequential frozen 
sections of either EG7 or EL4 tumors at diff  erent time points 
after adoptive transfer of GFP-OT1 cells (Fig. S5). The number 
Figure 5.  Distinct migratory patterns of T cells within tumors. 
(A) TPLSM images of OT1-GFP cells (green) within an EG7 tumor during 
the late phase of tumor rejection (day 5). Vessels (red) are labeled by 70 kD 
rhodamine-dextran. Several representative migration tracks of OT1-GFP 
cells are shown for cells either in close contact or not with blood vessels 
(green); individual tracks are plotted after normalization of their initial 
positions (bottom). Bar, 120 μm. (B) Scatter plot of the mean velocities of 
OT1 cells either in contact or not with blood vessels. ns, not signifi  cant. 
(C) Representative cell shapes of cells in close contact (right) or not (left) 
with the blood vessels (45 × 45 μm). Cells at distance or in close contact 
with blood vessels were tracked (mean = 10 min in both conditions), and 
the means of their elongation index during their migratory path were 
plotted (bottom). ***, P < 0.001. Bar, 28 μm. (D) Top graph shows the 
elongation index along time of representative cells migrating at distance 
(black) or in close contact (red) with blood vessels. Straight lines indicate 
the mean value of the elongation index for cells in close contact (1.9, red) or 
at distance (1.6, black) from blood vessels. Bottom graph shows the elon-
gation index along time of a representative cell that migrates fi  rst within 
the tumor matrix (black) and thereafter in close contact with a blood vessel 
(red). Straight line indicates the mean value of its elongation index (1.9, black).352  IN VIVO CYTOTOXIC T CELL IMAGING IN TUMORS | Boissonnas et al.
of GFP-OT1 cells was quantifi  ed according to the distance 
from the surface of the tumor (Fig. S5). Representative ex-
amples of OT1-GFP cells in tumor sections are shown in 
Fig. 6 A. During the early phase of rejection, most GFP-OT1 
cells were found within the fi  rst 200-μm peripheral sections 
of both EL4 and EG7 tumors (Fig. 6 B, top left). An accumu-
lation of lymphocytes in the periphery of solid tumors has 
been reported previously in other tumor models (33, 34), but 
the actual mechanisms for this preferential infi  ltration through 
the periphery are still unclear. To address possible macro-
scopic heterogeneities in tumor vessel distribution that might 
account for the peripheral infi  ltration pattern, we stained en-
dothelial cells in tumor sections using anti-CD31 antibody. 
We did not detect any signifi  cant diff  erence in the density of 
blood vessels (Fig. S6). This result, of course, does not ex-
clude functional diff  erences in the “permeability” of blood 
vessels to lymphocytes in diff  erent regions of the tumors.
In the late phase of rejection, similar to the early phase, 
most OT1-GFP cells infi  ltrating EL4 tumors remain in the 
periphery (Fig. 6 B, top right). In contrast, in the OVA-
  expressing EG7 tumors, an important redistribution of the 
CTLs is observed during the late phase. The density of OT1-
GFP cells in more central regions of the tumor increases, re-
sulting in a homogeneous distribution from the periphery 
to the tumor center. We conclude that CTLs infi  ltrate the 
  thymomas through the periphery and that deep tumor infi  l-
tration during rejection requires antigen expression by the 
tumor cells (since the OVA-negative EL4 tumors were not 
infi  ltrated deeply).
Antigen expression within the tumor causes the local ac-
tivation (increased CD69 expression), IFN-γ production, 
and cytotoxicity (tumor rejection) of OT1 cells (Fig. 1). To 
investigate if deep tumor infi  ltration requires antigen recog-
nition by individual T cells or is the consequence of overall 
modifi  cations in the tumor environment caused by antigen 
recognition by the CTLs, we analyzed the infi  ltration of EG7 
tumors by polyclonal, GFP-expressing T cells. The poly-
clonal T cells were activated in vitro and then adoptively 
transferred to EG7-bearing mice in the presence or absence 
of OT1 cells. At days 5–6 after transfer, tumor rejection 
started only in mice injected with polyclonal T cells and OT1 
cells (unpublished data). Strikingly, these polyclonal T cells 
accumulated and infi  ltrated the tumors deeply only in the 
presence of OT1 cells (Fig. S7). We conclude that OT1 cells 
Figure 6.  T cell infi  ltration through the periphery of tumors. OVA-
specifi  c OT1-GFP infi  ltration in EG7 and EL4 tumors (Thymoma) or MCA 
tumors (Fibrosarcoma), expressing or not the OVA epitope, during the 
early (day 3) and the late (day 6) phase of tumor rejection. (A) Repre-
sentative epifl  uorescence micrographs of EG7 and EL4 tumor sections 
(900 × 670 μm). The white line delimits tumor periphery. Bar, 210 μm. 
(B) Distribution of OT1-GFP cells across OVA-expressing (black) or non–OVA-
expressing tumors (white), during the early and the late phase of tumor 
rejection, 3 d (round) and 6 d (square) after adoptive transfer (mean ± SD, 
n = 3–8). ns, not signifi  cant. ***, P < 0.001.JEM VOL. 204, February 19, 2007  353
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induce a change in the antigen-expressing tumors, which makes 
them permissive to infi  ltration by other activated T cells.
If tumor infi  ltration occurs through the periphery of the 
tumors, tumor cell killing by CTLs should also start in the 
periphery. To address this possibility, we performed ordered 
frozen sections as in Fig. 6 and labeled apoptotic cells using 
tunnel. Apoptotic cells were most abundant in the periphery 
of EG7 tumors at the end of the early phase (Fig. 7 A). The 
number of tunnel-positive cells was counted in sequential 
sections and plotted as a function of the distance from the 
surface of the tumor. As shown in Fig. 7 B, tunnel-positive 
cells accumulated in the periphery of the EG7 tumors. Reduced 
accumulation of apoptotic cells was detected in the EL4 tumors. 
The low numbers of tunnel-positive cells detected in the 
  periphery of EL4 are most likely caused by the endogenous 
immune response. We conclude that apoptotic tumor cells 
accumulate in the periphery of the tumor, consistent with the 
peripheral infi  ltration of the CTLs evidenced in Fig. 6.
To extend our conclusions about the role of antigen in 
tumor infi  ltration to another tumor model, we used a fi  bro-
sarcoma tumor cell line, MCA-101, expressing (MCA-OVA) 
or not expressing (MCA) recombinant OVA. OT1-GFP 
cells adoptively transferred to tumor-bearing mice induce the 
rejection of MCA-OVA, but not MCA-tumors, with a ki-
netic similar to that of EG7 rejection (unpublished data). 
OT1 cells were recruited to both tumors, although the re-
cruitment to the OVA-expressing tumors was higher com-
pared with the control MCA tumors (Fig. S8). Similar to the 
thymoma model, OT1-GFP cells infi  ltrated the periphery of 
MCA tumors independently of antigen expression (Fig. 6 B, 
bottom left). OVA expression, however, was required for 
deep tumor infi  ltration at days 5–6 (Fig. 6 B, bottom right). 
Similar to the thymoma model, at days 3–4 tunnel-positive 
apoptotic tumor cells accumulated in the tumor periphery of 
antigen-expressing tumors (Fig. 7 B). We conclude that deep 
tumor infi  ltration, but not peripheral infi  ltration, requires an-
tigen expression by fi  brosarcoma tumor cells.
DISCUSSION
We show here that antigen expression by thymoma cells 
plays a critical role in the motility of CTLs, in the extent of 
infi  ltration, and in the distribution of the infi  ltrating CTLs. 
As suggested previously (33, 34), our results indicate that in-
fi  ltration by lymphocytes proceeds from the periphery of the 
tumors. Our results also support a novel working model for 
the dynamics of tumor infi  ltration in depth: after diapedesis 
from blood vessels in periphery of the tumor, CTLs encoun-
ter antigen-expressing tumor cells and arrest their migration 
for killing. Once tumors cells have been cleared in that re-
gion of the tumor, CTLs resume motility sometimes guided 
along collagen fi  bers and blood vessels until they reach other 
regions with living tumor cells. Because the killing starts in 
the tumor periphery, adjacent regions where tumor cells are 
alive are always toward the center of the tumor. We speculate 
that when arriving in a new region of the tumor where the 
tumor cells are alive, CTLs arrest their migration again and 
kill the antigen-expressing tumor cells. The overall result would 
be a displacement of the CTL population toward deeper 
  regions of the tumor. The repetition of this sequence of 
“motility” and “static/cytotoxic” phases would result in the 
progressive, oriented, antigen-dependent infi  ltration of the 
solid tumors that we have observed.
This model is mainly based on observations made on one 
single tumor—a mouse thymoma growing s.c. The topo-
graphy of infi  ltration observed in this thymoma was confi  rmed 
in the more relevant chemically induced fi  brosarcoma, MCA101. 
To date, the available imaging techniques impose the use 
of artifi  cial experimental models, including the transfer of 
  antigen-expressing tumors and the use of high numbers of 
transgenic T cells specifi  c for transfected antigens. The  analysis 
of mouse solid tumors more relevant to human cancers, spon-
taneous and growing in other locations, and the use of CTLs 
recognizing “true” tumor antigens is required to confi  rm or 
invalidate our model of CTL invasion.
In any case, this working model is still preliminary. It is 
unclear from our results whether the critical factor for the 
observed arrest in CTL motility and the deep tumor  infi  ltration 
is tumor cell killing or antigen recognition (and the resulting 
T cell activation). Experiments using control trans  genic CTLs 
with unrelated antigen specifi  city or CTLs defective for dif-
ferent functions (activation, cytokine secretion, cytotoxicity) 
should allow nailing down the precise requirements for CTL 
Figure 7.  Apoptotic cells after tumor T cell infi  ltration. Tunnel 
assay after adoptive transfer of OVA-specifi  c OT1 T cells in EG7 or MCA-
OVA tumor-bearing mice. (A) Typical epifl  uorescence images (900 × 670 μm, 
right and left; 225 × 167 μm, middle) of MCA-OVA tumor sections 4 d 
after transfer or not of OT1 cells: cell nuclei were labeled with Dapi 
(blue) and apoptotic cells (green) were labeled by using the FITC-Tunnel 
detection kit. Bar, 204 μm. (B) Representative quantifi  cation of apoptosis 
in thymoma or fi  brosarcoma (MCA-101) tumors expressing (closed symbols) 
or not (open symbols) the OVA epitope 4 d after OT1 cell transfer or 
not (control, crosses) (mean ± SD, three to four different tumors). The 
statistical differences between peripheral and deep regions for EG7 and 
MCA-OVA are indicated. ***, P < 0.001. 354  IN VIVO CYTOTOXIC T CELL IMAGING IN TUMORS | Boissonnas et al.
arrest on tumor cells and for tumor   infi  ltration in depth. Our 
experiment using polyclonal GFP-expressing cells suggests 
that T cells that do not induce rejection by themselves and do 
not infi  ltrate tumors in depth alone may still infi  ltrate tumors 
deeply in the course of rejection by other CTLs (Fig. S7).
It is therefore possible that T cell activation or cytokine 
secretion within the tumor, rather than tumor cell killing, is 
determinant for deep infi  ltration. Indeed, it has been  proposed 
that tumor infi  ltration by antigen-specifi  c CTLs triggers the 
invasion by other immune eff  ectors, including neutrophils, 
macrophages, and NK cells (26, 28, 29). It is therefore  possible 
that this “shell” of immune cells that modifi  es the tumor 
  microenvironment results in resumed CTL motility and deep 
infi  ltration. Our working model could be developed to 
  include the progressive formation of this shell of immune 
cells, which accompanies CTL infi  ltration and contributes to 
regained CTL motility and, thereby, to progression of the 
CTLs deeper into the tumor.
It is therefore critical to understand the mechanisms un-
derlying the observed peripheral infi  ltration during the early 
rejection phase. Although the density of blood vessels is not 
higher in the tumor periphery (Fig. S6), we cannot exclude 
that diff  erences in the permeability of the vessels in diff  erent 
regions of the tumor account for the observed CTL infi  ltra-
tion. It is likely, however, that the high permeability of 
the tumor vasculature results in the facilitated extravasations 
of the activated lymphocytes as soon as they enter the 
tumor,   favoring the peripheral infi  ltration. This peripheral in-
fi  ltration could also be a “feedback” favored by the local 
infl  am  mation, which is probably stronger in the periphery 
of the tumor, caused by tumor cell killing by CTLs. These 
peri  pheral CTLs would then proceed to infi  ltrate the tumor 
in depth through the mechanism depicted above. It is also 
possible, however, that as the CTLs, and most likely the 
rest of the antitumor immune response, proceeds deeply into 
the tumor, the permeability of the vessels is also progres-
sively increased.
Although it has been very diffi   cult thus far, it should be 
technically possible to analyze tumor cell killing in situ in real-
time. Indeed, our study has not addressed the frequency of the 
killing events, the kinetics of tumor cell killing, or the number 
of tumor cells killed by each CTL. Studies combining fl  uores-
cent tumor and stroma cells should also contribute to better 
understanding the interactions between the tumor and its close 
microenvironment. Future studies should also determine if the 
spatial and temporal organization of the invasion of other 
  tissues by eff  ector T cells, for example, in the course of auto-
immune disease or antiinfectious immune responses, follow 
the same rules that govern the infi  ltration of solid tumors.
MATERIALS AND METHODS
Mice. C57BL/6 mice were obtained from Charles River Laboratories. 
C57BL/6 Rag2–/– TCR (Vα2, Vβ5) transgenic mice (OT1) were crossed in 
the Curie Institute animal facility with UBI-GFP/BL6 or with the Actβ-
ECFP/BL6 (35) to obtain the F1 progeny (OT1-GFP and OT1-CFP mice, 
respectively). Live animal experiments were done in accordance to the 
guidelines of the French Veterinary Department.
Cells. CD8+ OT1 cells (specifi  c for the OVA257-264 peptide in a H2-Kb 
MHC class I context) were obtained from LNs of OT1 mice (purity  96%), 
and CD8+ OT1-GFP/CFP cells were purifi  ed (96% purity) using Myltenyi 
Biotec CD8+ magnetic cell sorting kit and injected retroorbitally in 6–8-wk-
old female C57BL/6 recipient tumor-bearing mice. EG-7 and EL-4 cell 
lines were stably transfected with a GFP coding plasmid and selected by cell 
sorting (97% GFP+ cells). The MCA101 (MCA) cell line was stably trans-
fected with an empty plasmid or a plasmid encoding for OVA coupled to the 
C1C2 domain of MFG-E8 to generate the control MCA and MCA-OVA, 
respectively. Injected s.c. MCA-OVA is actively rejected after OT1 adop-
tive transfer (unpublished data). Polyclonal cells were isolated from LNs of 
UBI-GFP/BL6 mice and were stimulated overnight in fl  at wells coated with 
1 μg/ml purifi  ed anti-CD3 and 1 μg/ml anti-CD28. All cell lines were cul-
tured in RPMI 1640+Glutamax I (GIBCO BRL) supplemented with addi-
tional antibiotics and 10% FCS. Tumor cells were injected s.c. in the fl  ank 
of mice (EL4 and EG7 in a contralateral manner), and tumor size was mea-
sured three times a week using the following formula:
  + ⎛⎞ ×× ⎜⎟
⎝⎠
1
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Flow cytometry. Phenotypic characterization of T cells was performed us-
ing a FACSCalibur (Becton Dickinson). EG7 and EL4 tumors, lymph node, 
and spleen were harvested at diff  erent days after adoptive transfer of OT1-
GFP naive cells. Cell suspensions were prepared in PBS 0.5% BSA, and cells 
were labeled with anti–CD69-biotin followed by streptavidin–PercP–Cy5.5, 
anti-CD62L–allophycocyanin, anti-CD44–PE, or anti-Vβ5–PE (Becton 
Dickinson). For intracellular cytokine staining, cell suspensions were incu-
bated for 3 h at 37°C in the presence of 5 μg/ml Brefeldin A, fi  xed in 4% 
PFA, and incubated in PBS 0.5% BSA with saponin at 0.1% in the presence 
of anti-IFN-γ–APC. CFSE staining was performed by incubating OT1 cells 
in PBS with 5 μM CFSE (Invitrogen) during 10 min at 37°C. CFSE was 
quenched and cells washed by adding large volume of culture medium and 
then centrifuged. Cells were diluted in PBS for injection.
Histological tumor analysis. The analysis of the distribution of OT1-
GFP cells, polyclonal GFP cells, and of CD31- or tunnel-positive cells across 
the tumors is illustrated in Fig. S5. Tumors were transversally and sagitally 
sectioned in the middle, fi  xed, frozen in Tissue-Tek OCT compound, and 
sectioned (5 μm) with a cryostat (Leica). For GFP quantifi  cation, 10 series 
of 10 contiguous images from the periphery to the center of each tumor, 
from 6 diff  erent sections, spaced from 10 to 20 μm (225 × 170μm) were 
acquired in the fi  rst 1,800 μm for EG7 and 1400 μm for MCA tumors. The 
periphery of the tumor was delimited by light transmission imaging. The 
density of OT1 cells across the tumor was calculated by normalizing the rela-
tive distribution of OT1 cells in each tumor to the mean of the global density 
for all tumors. For tunnel experiments, tumor sections were labeled using an 
in situ cell death detection kit (Roche) following manufacturer’s instructions. 
Endothelial cells were stained using purifi  ed anti-CD31 (Becton   Dickinson) 
or isotype control and a secondary antibody coupled with cyanin-3. Tumor 
sections were additionally stained with DAPI. Quantifi  cation was performed 
by calculating the fl  uorescent area of tunnel- and CD31-positive cells. A 
minimum of three diff  erent tumors were processed (analyzing one or two 
diff  erent sections per tumor), as for the analysis of GFP-positive cells.
Two-photon laser scanning microscopy. 107 naive OT1-GFP cells 
were retroorbitally injected to 6–8-wk-old female C57BL/6 recipients. 
  After 3 or 5–6 d after adoptive transfer, mice were anesthetized (initial dose 
of 80 mg/kg ketamine, 4 mg/kg xylazine, and 0.3 mg/kg fl  unitrazepan, fol-
lowed by a half-dose injection every 45 min; mice were kept under anesthesia 
during 3 h), and the tumor region was surgically exposed for two-photon 
imaging. Local temperature was monitored and maintained at 37°C. GFP/CFP-
labeled T cells could be detected up to 150 μm from the tumor’s surface. 
Vessels were stained by i.v. injection of 200 μl of 2.5 μg/ml rhodamine-
Dextran 70 kD (Sigma-Aldrich). In vivo PI staining was performed by JEM VOL. 204, February 19, 2007  355
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a slow intratumoral injection of 50 μl of a PBS solution at 1 mg/ml PI at 
distance of the analyzed area.
Measurements were performed in at least three independent experiments. 
The time-lapse two-photon laser-scanning microscopy (TPLSM) set-ups 
used were either a Fluoview200 (Olympus) in a descanned confi  guration 
equipped with a 20 × 0.95 NA dipping objective (Olympus), using a 540 nm 
dichroic mirror to separate GFP and Rodamine emission spectra, or an 
LSM510 Meta (Carl Zeiss MicroImaging, Inc.) coupled to a Maitai femto-
second laser (710–920 nm) (Spectra-Physics). With the latter confi  guration, 
SHG-GFP–Rhodamine fl  uorescence (Fig. 3) were separated using the Meta 
detector and were pixel-wise linear unmixed taken experimental fl  uores-
cence spectra of monolabeled samples as an external reference. Otherwise, 
three fl  uorescence channels were separated using 495 and 590 nm dichroic 
mirrors in combination with either 457/50 (SHG) or 472/30 (CFP), 520/35 
(GFP), and 624/40 nm bandpass fi  lters. The excitation wavelength was 
900 nm. For analysis of cell migration, every 30 s during 30–60 min, four 
consecutive 560 μm2 images, with 10-μm z-spacing using the 20× objec-
tive whose back aperture was artifi  cially underfi  lled to obtain an axial resolu-
tion near 5 μm. Images were average-projected using Image J (National 
Institutes of Health), and manual tracking of individual cells was performed 
using Metamorph software. Cells that could not be tracked for more than 
5 min were not considered to minimize projection errors inherent to the two-
  dimensional track analysis. The acquisition and analysis protocols for all ex-
perimental conditions to be compared were identical. The arrest coeffi   cient 
is defi  ned as the proportion of time each cell’s instantaneous velocity (calcu-
lated for every 30-s interval) is <2 μm/min. The confi  nement ratio corre-
sponds to the ratio of the distance between the initial and the fi  nal positions 
of each cell to the total distance covered by the same cell. The elongation 
index is defi  ned by the ratio between length of the long axis of the cell and 
length of the orthogonal short axis of the cell. Length and breadth of the cells 
were automatically calculated using Metamorph software after manually de-
limiting individual cells in each image.
Statistical analysis. Nonnormal distributions were compared using the 
Mann-Whitney rank sum test. The distributions of the time points of the 
trajectories in contact or at distance to the vessels (Fig. 5 A, bottom) were 
evaluated by calculating the correlation coeffi   cients. For histological analysis, 
paired Student’s t tests were performed to compare the distribution between 
peripheral region and deep region for each image series (*, P < 0.05; 
**, P < 0.01; ***, P <0.001; ns, not signifi  cant.)
Online supplemental material. Fig. S1 shows that OT1 cells are activated 
in the antigen-expressing tumor-draining lymph nodes. Fig. S2 quantifi  es 
OT1 T cell expansion in secondary lymphoid organs of tumor-bearing 
  animals. Fig. S3 characterizes the down-regulation of the TCR on OT1-GFP 
cells infi  ltrating the antigen-expressing tumors. Fig. S4 depicts the motility 
characteristics of the four categories of migrating OTI cells found in tumors. 
Fig. S5 illustrates the procedure of histological analysis used in Figs. 6 and 7 
and Figs. S6 and S7. Fig. S6 shows the analyses of the distribution of blood 
vessels in the tumors. Fig. S7 shows the infi  ltration of nonspecifi  c T cells in 
the presence or absence of antigen-specifi  c T cells. Fig. S8 shows the analyses 
of the density of OT1 cells in MCA-OVA and MCA tumors. Video S1–S4 
show migration of OT1-GFP eff  ector cells within EG7 tumor (Videos S1 
and S3) and EL4 tumor (Videos S2 and S4) during the early (Videos S1 and 
S2) and late (Videos S3 and S4) phases after adoptive transfer. Videos S5 and 
S6 show interaction of OT1-CFP eff  ector cells with GFP-EG7 tumor cells 
during the early and late phase after adoptive transfer, respectively. Video S7 
shows shape modifi  cations of OT1-GFP eff  ector cells migrating within an 
EG7 tumor during the late phase after adoptive transfer. Video S8 shows 
OT1-GFP eff  ector cells dividing within an EG7 tumor during the late phase 
after adoptive transfer. Video S9 shows OT1-GFP eff  ector cells migrating in 
close contact with blood vessels within an EG7 tumor during the late phase 
of tumor rejection. Video S10 shows a three-dimensional reconstruction 
from Video S9. Video S11 shows examples of OT1-GFP eff  ector  cells 
  migrating from blood vessels toward the EG7 tumor matrix during the late 
phase after adoptive transfer. Video S12 shows typical shapes of OT1-GFP 
eff  ector cells migrating either in contact or not with blood vessels within an 
EG7 tumor during the late phase after adoptive transfer.
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